|
|||||||||
|
|||||||||
 | |||||||||
 |
|
News
Analysis
Biopharmaceuticals are beginning to
come off patent, promising cost savings for patients and headaches for regulators... Rheumatology News Fully 18% of patients who use
NSAIDs do not report them to clinicians... Eli Lilly and Co and MacroGenics,
Inc have entered into a global strategic alliance to develop and commercialize teplizumab (MGA031 or hOKT3¦Ã1(Ala-Ala)), a humanized, non-Fc
receptor binding, anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules, for use in the treatment of
multiple T¨Ccell-mediated autoimmune diseases... Arthritis accounts for up
to 15% of lost work days in some states, and a median 33% of adults with arthritis report Hollis-Eden Pharmaceuticals, Inc, a company
focused on the development of a proprietary new class of small molecules that are metabolites or synthetic analogs of endogenous
adrenal steroid hormones, announced additional data on drug candidate HE3286 (Triolex), an orally active, second generation,
synthetic 17- ethynyl derivative of the steroid hormone dehydroepiandrosterone (DHEA), currently in preclinical and clinical
study for the treatment of autoimmune diseases and inflammatory disorders...
|
|
 |
|
 Rheumatology and Infusion Therapy: Practice and Treatment Choices in the New Era | |
 The Scientific Basis of Individualized Treatment of Patients With RA: Online Byte-Size CME | |
To remove your e- mail address from our mailing list, please send a blank email to unsubscribe@fbhc.org. For questions and comments regarding this newsletter please contact info@ciaomed.org | |
